CN116687906A - ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 - Google Patents

ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 Download PDF

Info

Publication number
CN116687906A
CN116687906A CN202310897135.1A CN202310897135A CN116687906A CN 116687906 A CN116687906 A CN 116687906A CN 202310897135 A CN202310897135 A CN 202310897135A CN 116687906 A CN116687906 A CN 116687906A
Authority
CN
China
Prior art keywords
sigma
receptor
anavex2
treatment
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310897135.1A
Other languages
English (en)
Chinese (zh)
Inventor
G·內利阿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anavex Life Sciences Corp
Original Assignee
Anavex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57834974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116687906(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anavex Life Sciences Corp filed Critical Anavex Life Sciences Corp
Publication of CN116687906A publication Critical patent/CN116687906A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN202310897135.1A 2015-07-22 2016-07-19 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 Pending CN116687906A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562195417P 2015-07-22 2015-07-22
US62/195,417 2015-07-22
PCT/IB2016/001158 WO2017013496A1 (en) 2015-07-22 2016-07-19 Enantiomers of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine (anavex2-73) and use thereof in the treatment of alzheimer's disease and other disorders modulated by the sigma 1 receptor
CN201680033151.4A CN107708687A (zh) 2015-07-22 2016-07-19 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680033151.4A Division CN107708687A (zh) 2015-07-22 2016-07-19 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Publications (1)

Publication Number Publication Date
CN116687906A true CN116687906A (zh) 2023-09-05

Family

ID=57834974

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310897135.1A Pending CN116687906A (zh) 2015-07-22 2016-07-19 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
CN201680033151.4A Pending CN107708687A (zh) 2015-07-22 2016-07-19 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680033151.4A Pending CN107708687A (zh) 2015-07-22 2016-07-19 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Country Status (7)

Country Link
US (3) US11617734B2 (enExample)
EP (2) EP3324956B1 (enExample)
JP (4) JP7429942B2 (enExample)
CN (2) CN116687906A (enExample)
CA (1) CA2986345A1 (enExample)
HK (1) HK1247847A1 (enExample)
WO (1) WO2017013496A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4616852A3 (en) 2015-07-22 2025-10-22 Anavex Life Sciences Corp. Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
US11617734B2 (en) * 2015-07-22 2023-04-04 Anavex Life Sciences Corp. Enantiomers of A2-73, analogues, and sigma agonist activity
AU2018375667B2 (en) * 2017-11-28 2023-03-02 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
US12383526B2 (en) 2018-05-18 2025-08-12 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
WO2021158586A1 (en) 2020-02-04 2021-08-12 Teva Pharmaceuticals International Gmbh Solid state forms of blarcamesine salts
WO2025117826A1 (en) * 2023-11-30 2025-06-05 Anavex Life Sciences Corp. Methods of using surrogate biomarkers in sigma-1 receptor therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008044A1 (en) * 2011-07-08 2013-01-17 Anavex Life Sciences Corp. Synthesis of (+) and (-) 1 -(5,5-diphenyltetrahydrofuran-3- yl)-n,n-dimethylmethanamine, (+) and (-) 1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n- dimethylmethanamine and (+) and (-) 1-(2,2- dffhenyltetrahydrofuran-3-yl)-n-metihylmethanamine
WO2014155138A1 (en) * 2013-03-28 2014-10-02 Alexandre Vamvakides Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands
CN107708687A (zh) * 2015-07-22 2018-02-16 阿纳韦克斯生命科学公司 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636625B1 (fr) 1988-09-01 1990-11-09 Jouveinal Sa Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese
GR1002616B (el) * 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
US20110206780A1 (en) 2010-01-06 2011-08-25 Auspex Pharmaceuticals, Inc. Morphinan modulators of nmda receptors, sigma1 receptors, sigma2 receptors, and/or a3b4 nicotinic receptors
US20140378460A1 (en) 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
FR2983732B1 (fr) 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008044A1 (en) * 2011-07-08 2013-01-17 Anavex Life Sciences Corp. Synthesis of (+) and (-) 1 -(5,5-diphenyltetrahydrofuran-3- yl)-n,n-dimethylmethanamine, (+) and (-) 1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n- dimethylmethanamine and (+) and (-) 1-(2,2- dffhenyltetrahydrofuran-3-yl)-n-metihylmethanamine
WO2014155138A1 (en) * 2013-03-28 2014-10-02 Alexandre Vamvakides Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands
CN107708687A (zh) * 2015-07-22 2018-02-16 阿纳韦克斯生命科学公司 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Also Published As

Publication number Publication date
EP4484953A3 (en) 2025-03-12
JP2018524306A (ja) 2018-08-30
CA2986345A1 (en) 2017-01-26
CN107708687A (zh) 2018-02-16
US20250120938A1 (en) 2025-04-17
US20230044710A1 (en) 2023-02-09
EP3324956A4 (en) 2019-02-20
US11617734B2 (en) 2023-04-04
WO2017013496A1 (en) 2017-01-26
JP2023073373A (ja) 2023-05-25
US20180169059A1 (en) 2018-06-21
HK1247847A1 (zh) 2018-10-05
EP3324956B1 (en) 2024-11-20
EP3324956A1 (en) 2018-05-30
JP2025061540A (ja) 2025-04-10
US12208079B2 (en) 2025-01-28
JP7627963B2 (ja) 2025-02-07
JP2021152077A (ja) 2021-09-30
JP7429942B2 (ja) 2024-02-09
EP4484953A2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP7627963B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
US20220202798A1 (en) Use of pridopidine for the treatment of fragile x syndrome
ES2678794T3 (es) Terapia para trastornos neurológicos basada en baclofeno y acamprosato
CN105744932B (zh) 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物
KR102014875B1 (ko) 파킨슨병을 치료하기 위한 신규의 치료적 접근법
CN108420819A (zh) 用于治疗神经障碍的新组合物
EP2948135A1 (en) Compositions and methods for the treatment of pervasive development disorders
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
CA2957224A1 (en) Method of treating prader-willi syndrome
US20250082688A1 (en) Compositions and methods for williams syndrome (ws) therapy
CN105592849A (zh) 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
WO2023202102A1 (zh) 倍半萜类化合物在抑制trpa1通道的活性中的应用
HK40097673A (en) Enantiomers of anavex2-73 and use thereof in the treatment of alzheimer's disease and other disorders modulated by the sigma 1 receptor
TW202027752A (zh) 使用ccr-3抑制劑治療老化相關損傷之方法及組合物
WO2011147999A1 (es) Compuesto inhibidor de la activación de la enzima erk1/2 para su uso en el tratamiento de enfermedades neurodegenerativas
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40097673

Country of ref document: HK